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Abstract. Thyroid cancer (TC) is the most frequent endocrine 
malignancy, accounting however for only 1-2% of all human 
cancers, and the best-established risk factor for TC is radia-
tion exposure, particularly during childhood. Since the BER 
pathway seems to play an important role in the repair of DNA 
damage induced by IR and other genotoxicants, we carried 
out a hospital-based case-control study in order to evaluate 
the potential modifying role of 6 BER polymorphisms on 
the individual susceptibility to non-familial TC in 109 TC 
patients receiving iodine-131, and 217 controls matched 
for age (±2 years), gender and ethnicity. Our results do not 
reveal a significant involvement of XRCC1 Arg194Trp and 
Arg399Gln, OGG1 Ser326Cys, APEX1 Asp148Glu, MUTYH 
Gln335His and PARP1 Val762Ala polymorphisms on the indi-
vidual susceptibility towards TC, mostly in aggreement with 
the limited available evidence. By histological stratification 
analyis, we observed that the association between the presence 
of heterozygozity in the MUTYH Gln335His polymorphism 
and TC risk almost reached significance for the papillary 
subtype of TC. This was the first time that the putative asso-
ciation between this polymorphism and TC susceptibility 
was evaluated. However, since the sample size was modest, 
the possibility of a type I error should not be excluded and 
this result should, therefore, be interpreted with caution. 
More in depth studies involving larger populations should be 
pursued in order to further clarify the potential usefulness of 
the MUTYH Gln335His genotype as a predictive biomarker 
of susceptibility to TC and the role of the remaining BER 
polymorphisms on TC susceptibility.
Introduction
Thyroid cancer (TC) is the most frequent endocrine malig-
nancy, accounting however for only 1-2% of all human cancers. 
In contrast with most malignancies, increasing incidence 
rates have been consistently reported worldwide over recent 
decades, although mortality due to TC does not seem to follow 
this trend (1). TC arises mostly from the epithelial elements of 
the gland and is usually classified according to histological and 
clinical criteria (1). Papillary and follicular thyroid carcinomas 
are the most common histological varieties, with papillary TC 
representing about 85% of all cases. TC is unusual during 
childhood but incidence increases with age. Also, women 
are afflicted three times as often as men, particularly during 
reproductive years (1). Overall prognosis is generally good, 
except for undifferentiated (anaplastic) carcinomas, which 
account for <5% of TC cases (1).
TC etiology remains an obscure subject: inherited familial 
factors such as germline mutations seem to be responsible 
for only a minor percentage of TC cases (2,3). Hormonal and 
dietary factors (e.g. iodine intake) have also been suggested 
to be implicated in the etiology of the disease but evidence 
is limited and inconsistent or, in the best of cases, limited to 
specific subtypes of TC (1,2). Clearly, the best-established 
risk factor for TC is radiation exposure, particularly during 
childhood: risk of TC is increased after exposure to ionizing 
radiation (IR) doses as low as 0.1 Gy and is both dose- and age- 
dependent, being maximal about 20-30 years after exposure 
(1,2). This long latency period between radiation exposure and 
TC diagnosis is expected since IR induces mostly recessive 
mutations, therefore, requiring a second event for tumor initia-
tion (4). Even so, radiation exposure is estimated to account for 
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<10% of all TC, suggesting that other risk factors could also 
have a relevant impact in the etiology of this malignancy.
Since TC risk and frequency is significantly higher in 
relatives (particularly first-degree) of TC patients compared 
to the general population (2,3,5), it is possible that high-
prevalence, low-penetrance genetic variations could also 
constitute predisposing factors for TC, specially when 
considered together with exposure to environmental risk 
factors such as IR. Germ-line DNA polymorphisms in genes 
involved in regulation of apoptosis and control of the cell 
cycle (e.g. TP53), in kinase-dependent signaling pathways 
(e.g. RET), in endobiotic or xenobiotic metabolism (e.g. GST 
and CYP superfamilies), in hormonal and iodine metabolism 
(e.g. TG) and in DNA repair (among others) have been asso-
ciated with interindividual differences in TC risk (reviewed 
in refs. 3, 5). Also, in the first genome-wide association study 
ever performed on TC, two polymorphisms located near the 
FOXE1 (TTF-2) and NKX2-1 (TTF-1) genes (which encode 
for thyroid-specific transcription factors) were identified 
as strong genetic risk markers of sporadic papillary TC in 
European populations (6).
IR is considered mutagenic since it can cause damage to 
DNA either directly, introducing single and double-strand 
breaks (DSB) to the DNA helix, or indirectly, promoting the 
radiolysis of water to yield radicalar DNA-reactive species 
that cause oxidative base damage (4). Such DNA lesions can 
activate specific checkpoints, triggering cell cycle arrest, in 
order to allow for DNA damage repair or, ultimately, inducing 
apoptotic cell death. Cell replication in the presence of genetic 
errors can cause irreversible mutations, leading to malignant 
transformation (7). In line with this, significant increase in 
DNA damage was found in patients with TC (8), suggesting 
that DNA repair mechanisms are important in correcting 
DNA damage and that defective DNA repair capacity might 
contribute to the risk of TC.
Base excision repair (BER) and DSB repair pathways are 
especially important in re-establishing DNA integrity after 
irradiation (7,9). The latter can be accomplished through 
homologous recombination, in which the double helix of the 
homologous, undamaged partner DNA molecule is used as a 
model, or through non-homologous end-joining repair, which 
involves direct ligation of the two double-strand-break ends 
(7,9). The BER pathway, in turn, is the main pathway respon-
sible for recognizing, excising, and repairing small chemical 
alterations of a single base (e.g. oxidative DNA damage) 
caused by free radicals formed endogenously or after exposure 
to exogenous agents such as IR (7,9,10). Briefly, BER is a multi-
step process involving several proteins, such as 8-oxoguanine 
DNA glycosylase (OGG1), APEX nuclease (multifunctional 
DNA repair enzyme) 1 (APEX1), X-ray repair complementing 
defective repair in Chinese hamster cells 1 (XRCC1) or poly 
(ADP-ribose) polymerase (PARP1), that act via a number of 
coordinated sequential ‘cut-and-patch’-type reactions to detect 
the lesion, remove the single damaged base, and fill in the 
resulting single-stranded gap using the intact complementary 
strand as template (7,9-11).
As such, DNA repair polymorphisms that modulate the 
DNA repair capacity may contribute to individual suscep-
tibility to DNA damaging agents and, hence, modify cancer 
risk. In fact, polymorphic variants in virtually all DNA repair 
pathways have been associated with susceptibility for several 
types of cancer (7), including TC: regarding the latter, for 
example, polymorphisms in DNA repair genes such as ERCC2 
(12) (NER pathway), Ku80 (13) (NHEJ pathway), XRCC3 
(14), BRCA1 (15) and possibly RAD51 (14) (HR pathway) 
have been associated with TC risk (reviewed in refs. 3,5,9,16). 
Considering the BER pathway, in particular, several of the 
genetic variants identified in the XRCC1, OGG1, MUTYH, 
APEX1 and PARP1 genes have been reported to be associated 
with individual susceptibility to a variety of cancers, including 
breast, lung, colorectal and skin cancers (7,10,11). Some of 
these polymorphisms also seem to affect IR sensitivity (17,18). 
However, only a very limited number of studies have been 
published focusing on a possible role of BER pathway SNPs on 
TC susceptibility, mostly with negative or inconclusive results, 
except for XRCC1 polymorphisms (reviewed in refs. 3,9,16).
Since the BER pathway seems to play an important role in 
the repair of DNA damage induced by IR (the most well-known 
risk factor for TC) and other genotoxicants, we carried out an 
hospital based case-control study in a Caucasian Portuguese 
population in order to evaluate the potential modifying role 
of 6 BER polymorphisms on the individual susceptibility to 
non-familial TC.
Materials and methods
Study subjects. One hundred and nine TC patients receiving 
iodine-131 treatment at the Department of Nuclear Medicine 
of the Portuguese Oncology Institute of Lisbon were recruited. 
None of the patients enrolled in this study presented familiar 
history of TC. The TC diagnosis was confirmed histologically. 
For each case (except for one), two controls were recruited at 
São Francisco Xavier Hospital (Department of Laboratory 
Medicine), matched for age (±2 years), gender and ethnicity. 
Inclusion criteria for the control group included absence of 
cancer or thyroid disease and no familiar history of thyroid 
pathology. All study subjects were Caucasian, Portuguese, 
with Portuguese ascendants and no previous history of onco-
logic disease.
The anonymity of the patients and control population 
was guaranteed. Both patient and control participants groups 
were submitted to a questionnaire, performed by trained 
interviewers, in order to collect information on demographic 
characteristics, family history of cancer, lifestyle habits 
(smoking and alcohol drinking) and exposure to IR. In respect 
to smoking habits, former smokers were considered as non-
smokers if they gave up smoking either 2 years before TC 
diagnosis or 2 years before the inclusion date as control.
For all eligible participants, written informed consent was 
obtained prior to blood withdrawal. The response rate was 
>95% for cases and controls. This study was approved by the 
ethics board of the involved institutions.
DNA extraction. Peripheral blood samples from all study 
participants were collected into 10-ml heparinized tubes and 
kept thereafter at -80˚C. Genomic DNA was extracted from 
250 µl of each blood sample using a commercially available 
kit (QIAamp® DNA mini kit; Qiagen), according to the manu-
facturer's instructions. All DNA samples were stored at -20˚C 
until further analysis.
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Single nucleotide polymorphisms (SNP's) selection. Publicly 
available on-line databases such as NCBI (http://www.ncbi.
nlm.nih.gov/snp/), GeneCards (http://www.genecards.org) and 
SNP500Cancer (http://variantgps.nci.nih.gov/cgfseq/pages/
snp500.do) were used to search for SNPs reported to date on 
genes coding for DNA repair proteins of the BER pathway. 
Eligible SNPs had to be located in a coding region, give 
rise to an amino acid change (non-synonymous) and exhibit 
a minor allele frequency >0.1 in Caucasian populations. 
According to these criteria, 6 common nsSNPs were selected 
for genotyping: Arg194Trp [reference SNP no. (rs) 1799782] 
and Arg399Gln (rs25487) for XRCC1; Ser326Cys (rs1052133) 
for OGG1; Asp148Glu (rs1130409) for APEX1; Gln335His 
(rs3219489) for MUTYH and Val762Ala (rs1136410) for 
PARP1 (Table I).
Genotyping. PCR-RFLP-XRCC1 Arg194Trp, XRCC1 
Arg399Gln and OGG1 Ser326Cys polymorphisms were 
genotyped by polymerase chain reaction (PCR) followed by 
restriction fragment length polymorphism (RFLP). Primer 
design and PCR conditions were optimized in order to achieve 
the best possible results: OligoAnalyzer 3.1 (http://eu.idtdna.
com/analyzer/Applications/OligoAnalyzer/) was used to 
determine melting temperatures, GC contents, hairpins, and 
dimmer formation. Basic local alignment search tool (BLAST) 
resource (http://blast.ncbi.nlm.nih.gov/Blast.cgi) was used to 
confirm low similarity with other human sequences. All PCR 
reactions were performed in a 50 µl final volume, comprising 
3 µl genomic DNA, 1X ImmoBuffer, 2.5 mM MgCl2, 
0.8 mM of each dNTP (Bioline), 0.6 µM of each primer 
(Stabvida), 0.909 µl DMSO and 0.75 U of Immolase (Bioline). 
Amplification was accomplished in a GeneAmp® PCR system 
2700 thermal cycler (Applied Biosystems): the initial enzyme 
activation step (95˚C, 7 min) was ensued by a variable number 
of amplification cycles consisting of denaturation (94˚C, 
30 sec), annealing (variable temperature, 30 sec) and exten-
sion (72˚C, 30 sec); amplification was concluded with a final 
extension step at 72˚C for 10 min. Primer sequences, annealing 
temperatures, number of amplification cycles (PCR condi-
tions) and PCR product size (bp) specific for both XRCC1 
polymorphisms have been described elsewhere (19). Specific 
primer sequences (forward: 5'-ggt ggc cct aaa gga ctc tcc-3'; 
reverse: 5'-cca tcc tta gcg ctg tct ccc-3') and PCR conditions 
(35 PCR cycles, with an annealing temperature of 64˚C) were 
used for the determination of OGG1 Ser326Cys genotype, 
yelding a 456 bp PCR product.
After amplification, 10 µl of each PCR product were 
incubated with 5 units of an appropriate restriction enzyme 
and 1.25 µl of the 10X buffer recommended by the enzyme 
manufacturer, to a final volume of 12.5 µl. The choice of the 
restriction enzyme and reaction conditions were optimized as 
follows: to genotype the XRCC1 Arg194Trp polymorphism, 
the previously amplified fragment was digested with MspI 
(Fermentas) for 2 h at 37˚C. The exact same conditions were 
applied to the restriction analysis of the XRCC1 Arg399Gln 
polymorphism while for the OGG1 Ser326Cys polymorphism 
the digestion was performed overnight at 37˚C with the SatI 
restriction enzyme (Fermentas).
After restriction enzyme inactivation (20 min at 65˚C), 
the resulting digested fragments were electrophoresed in an 
ethidium bromide-stained 4% agarose gel and visualized 
under ultraviolet light. HyperLadder V (Bioline) was used as 
molecular marker. The expected digestion pattern for each 
genotype of the XRCC1 Arg194Trp and XRCC1 Arg399Gln 
polymorphisms has been previously described (19). For the 
OGG1 Ser326Cys polymorphism, fragment length after SatI 
digestion was 456 bp for the C/C genotype, 456, 258, 198 bp 
for the C/G genotype and 258, 198 bp for the G/G genotype.
All the genotype determinations were carried out twice 
in independent experiments and inconclusive samples were 
re-analysed.
Real-time PCR-APEX1 Asp148Glu, MUTYH Gln335His 
and PARP1 Val762Ala polymorphisms were genotyped by 
real-time PCR, using the TaqMan fluorogenic 5' nuclease assay 
(Applied Biosystems). In order to assure uniformity in genomic 
DNA content (2.5 ng.µl-1) in all samples analyzed through 
this method, DNA was pre-quantified by fluorimetry with the 
Quant-iT™ PicoGreen® dsDNA Assay kit (Invitrogen) and 
a Zenyth 3100 plate reader (Anthos Labtech Instruments), 
according to the manufacturer's instructions.
Amplification was carried out in a 7300 Real-Time PCR 
System thermal cycler (Applied Biosystems), with 96-well 
microplates containing 10 ng of genomic DNA, 1X SNP 
genotyping assay mix (APEX1 assay ID: C___8921503_10; 
MUTYH assay ID: C__27504565_10; PARP1 assay 
ID: C___1515368_1_) and 1X TaqMan Universal PCR Master 
mix per well (final volume, 10 µl/well). Initial enzyme activa-
tion (10 min, at 95˚C) was ensued by 40 cycles of denaturation 
Table I. Selected SNP's and detailed information on the corresponding base and amino acid exchanges as well as minor allele 
frequency.
Gene Region Codon Base (amino acid) exchange Minor allele frequency, MAF (%)a
XRCC1 Exon 6 194 C➝T (Arg➝Trp) 13.1
 Exon 10 399 G➝A (Arg➝Gln) 26.6
OGG1 Exon 6 326 C➝G (Ser➝Cys) 29.9
APEX1 Exon 5 148 T➝G (Asp➝Glu) 44.0
MUTYH Exon 12 335 G➝C (Gln➝His) 31.9
PARP1 Exon 17 762 T➝C (Val➝Ala) 24.4
aAccording to http://www.ncbi.nlm.nih.gov/projects/SNP/.
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(15 sec at 92˚C) and probe annealing/extension (1 min at 60˚C). 
Allelic discrimination was then performed by measuring 
fluorescence emitted by both VIC and FAM dyes in each 
well (60 sec) and computing the results into the System SDS 
software version 1.3.1. All reactions were performed twice 
in independent experiments and repeated for all inconclusive 
samples.
Statistical analysis. Exact probability tests available in Mendel 
software (V5.7.2) were used to analyze the Hardy-Weinberg 
frequencies for XRCC1, OGG1, APEX1, MUTYH and PARP1 
alleles in patient and control populations, considered sepa-
rately (20).
The differences in genotype frequency and smoking status 
between patient and control populations were evaluated by 
the Chi-square test. The normality of continuous variables, 
such as age, and the homogeneity of variances were analyzed 
with Kolmogorov-Smirnov and Levene tests, respectively. 
The Student's t-test was used in the statistical analysis of the 
homogeneity of age distribution between patient and control 
populations, while the Chi-square test was applied to the 
analysis of the homogeneity of gender distribution.
When assessing the genetic effects, logistic regression 
analysis was performed to determine the crude and adjusted 
odds ratio (OR) and the corresponding 95% confidence 
intervals (CI). Adjusted OR calculations took into account 
gender, age at diagnosis (≤30, 31-49, 50-69 and ≥70 years) and 
smoking habits (smokers/non-smokers), with female gender, 
lower age group and non-smokers being considered as the 
Table II. General characteristics for the TC cases (n=109) and 
control population (n=217).
Characteristics Cases, n (%) Controls, n (%) P-valuec,d
Gender
  Female 92 (84.4) 185 (85.3) 0.839
  Male 17 (15.6) 32 (14.7)
Agea,b
  ≤30 4 (3.7) 9 (4.1) 0.997
  31-49 39 (35.8) 77 (35.5)
  50-69 52 (47.7) 104 (47.9)
  ≥70 14 (12.8) 27 (12.4)
Smoking habits
  Non-smoker 97 (89) 177 (82.3) 0.117
  Smoker 12 (11) 38 (17.7)
  Missing 0 2 (0.6)
aAge at diagnosis for cases. bAge at enrollment for each of the case-
matched controls. cSee Materials and methods; dcases vs. control 
group.
Table ΙΙΙ. Genotype frequencies for each of the selected BER polymorphisms in TC case and control populations.
 Genotype frequency
 -----------------------------------------------------------------------------------------------------------------------------
 Reference  Reference  Variant
Polymorphism forma n homozygote, n (%) Heterozygote, n (%) homozygote, n (%) P-valueb
XRCC1 (Arg194Trp)
Control group Arg 217 196 (90.3) 21 (9.7) 0 (0.0) 0.109
Case group  108 98 (90.7) 8 7.4) 2 (1.9)
XRCC1 (Arg399Gln)
Control group Arg 217 87 (40.1) 105 (48.4) 25 (11.5) 0.911
Case group  109 46 (42.2) 50 (45.9) 13 (11.9)
OGG1 (Ser326Cys)
Control group Ser 217 139 (64.1) 78 (35.9) 0 (0.0) 0.335
Case group  108 75 (69.4) 33 (30.6) 0 (0.0)
APEX1 (Asp148Glu)
Control group Asp 217 56 (25.8) 103 (47.5) 58 (26.7) 0.810
Case group  109 31 (28.4) 52 (47.7) 26 (23.9)
MUTYH (Gln335His)
Control group His 216 106 (49.1)  102 (47.2) 8 (3.7) 0.195
Case group  109 64 (58.7)  40 (36.7) 5 (4.6)
PARP1 (Val762Ala)
Control group Val 216 168 (77.8) 48 (22.2) 0 (0.0) 0.270
Case group  108 78 (72.2) 30 (27.8) 0 (0.0)
aReference form was defined as the residue corresponding to the most frequent genotype in the TC case population. bChi-square test for 
distribution of genotypic frequencies.
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reference groups for each of these variables. For the purpose 
of these calculations, age at diagnosis for controls was the age 
at enrollment.
All analyses were performed using the Statistical Package 
for the Social Sciences for Windows 15.0 version (SPSS, Inc., 
Chicago IL, USA).
Results
This study comprised 109 TC patients and 217 age- and gender-
matched controls. According to histological criteria, 71% TC 
cases were classified as papillary TC (78 patients), 26% as 
follicular TC (28 patients) and 3% as poorly differentiated TC 
(3 patients). Previous exposure to IR sources, with the excep-
tion for diagnostic medical X-rays, was denied by all cases.
The baseline characteristics (gender, age and smoking 
habits) of both case and control populations are listed in 
Table II. The case group included 17 male and 92 female 
patients, with an overall mean age of 53 years. In agreement 
with the gender distribution usually observed in this type of 
cancer, the frequency of females in the case group was signifi-
cantly higher than the frequency of males. No significant 
difference was found between the case and control groups 
concerning age distribution (P=0.997), gender (P=0.839) or 
smoking habits (P=0.117).
The genotype frequencies of the 6 polymorphisms, in both 
TC cases and controls, are shown in Table III. The frequency 
of minor allele homozygotes for the OGG1 Ser326Cys and 
PARP1 Val762Ala polymorphisms was null both in case and 
control study groups. The same was observed for the XRCC1 
Arg194Trp polymorphism in the control group. The genotypic 
frequencies of the XRCC1 Arg399Gln, APEX1 Asp148Glu 
and PARP1 Val762Ala polymorphisms in control and cancer 
groups were in agreement with the expectations of the Hardy-
Weinberg law (P>0.1, exact probability test). The same was 
not observed, however, for the OGG1 Ser326Cys and MUTYH 
Gln335His polymorphisms in the control group nor for the 
XRCC1 Arg194Trp polymorphism in the cancer group.
The genotypic frequencies that were observed in the control 
group for the XRCC1 Arg194Trp and XRCC1 Arg399Gln 
polymorphisms are similar to those previously reported by 
Kiuru et al (21) for a Causasian Northern European popula-
tion. The genotypic frequencies of the OGG1 Ser326Cys, 
APEX1 Asp148Glu and PARP1 Val762Ala polymorphisms 
are also in agreement with those reported in a larger study 
(n>1000) carried out in a Caucasian American population (22). 
As for the MUTYH Gln335His polymorphism, the genotypic 
frequencies reported are in agreement with those reported by 
Conde et al (23), for a similar Caucasian Portuguese popula-
tion (Table IV).
Table IV. Comparison of genotypic frequencies observed in the control group of this study with those previously published in the 
literature for Caucasian populations.
Polymorphism Genotype frequency Population
 Arg/Arg, n (%) Trp/Arg, n (%) Trp/Trp, n (%)
 --------------------------------------------------------------------------------------------------
XRCC1 (Arg194Trp) 196 (90.3) 21 (9.7) 0 (0.0) Caucasian Portuguese (study data)
 1377 (88.5) 177 (11.4) 2 (0.1) Caucasian Northern European (n=1556) (21)
 Arg/Arg, n (%) Arg/Gln, n (%) Gln/Gln, n (%)
 --------------------------------------------------------------------------------------------------
XRCC1 (Arg399Gln) 87 (40.1) 105 (48.4) 25 (11.5) Caucasian Portuguese (study data)
 645 (41.6) 728 (47.0) 176 (11.4) Caucasian Northern European (n=1549) (21)
 Ser/Ser, n (%) Ser/Cys, n (%) Cys/Cys, n (%)
 -------------------------------------------------------------------------------------------------
OGG1 (Ser326Cys) 139 (64.1) 78 (35.9) 0 (0.0) Caucasian Portuguese (study data)
 760 (61.1) 424 (34.1) 60 (4.8) Caucasian American (n=1244) (22)
 Asp/Asp, n (%) Asp/ Glu, n (%) Glu/Glu, n (%)
 --------------------------------------------------------------------------------------------------
APEX1 (Asp148Glu) 56 (25.8) 103 (47.5) 58 (26.7) Caucasian Portuguese (study data)
 327 (27.09) 590 (48.88) 290 (24.03) Caucasian American (n=1207) (22)
 Gln/Gln, n (%) Gln/His, n (%) His/His, n (%)
 ---------------------------------------------------------------------------------------------------
MUTYH (Gln335His) 8 (3.7) 102 (47.2) 106 (49.1) Caucasian Portuguese (study data)
 29 (5.3) 235 (43.0) 283 (51.7) Caucasian Portuguese (n=547, only women) (23)
 Val/Val, n (%) Val/Ala, n (%) Ala/Ala, n (%)
 ---------------------------------------------------------------------------------------------------
PARP1 (Val762Ala) 168 (77.8) 48 (22.2) 0 (0.0) Caucasian Portuguese (study data)
 963 (70.2) 361 (26.3) 47 (3.4) Caucasian American (n=1371) (22)
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Since TC incidence is recurrently reported to be higher in 
women (which was also the predominant gender in our case 
group), we also compared genotypic frequencies according 
to gender among TC patients (in order to examine for any 
gender-specific genetic effect). The frequency of the different 
genotypes considered did not differ significantly with gender 
in TC patients (Chi-square test with Yates correction), even 
after TC stratification according to histological criteria (data 
not shown). For this reason, no further gender stratification of 
the population was considered in the statistical analysis.
As shown in Table V, no significant differences in genotypic 
frequencies were observed for any of the 6 selected poly-
morphisms, between cases and controls (P>0.05, Chi-square 
test with Yates correction). Stratifying the data according 
to the histological classification of the tumors (papillary 
and follicular tumors) did not yield any significant results, 
irrespective of the polymorphism considered. Therefore, the 
results obtained concerning the genotype distributions for any 
of the selected polymorphisms in TC patients, when compared 
to controls, do not support an association between the presence 
of one genotype of any of these polymorphisms and individual 
susceptibility towards TC.
In addition, logistic regression analysis concerning the 
effect of the different polymorphisms on TC risk (adjusted for 
age at diagnosis, smoking habits and gender) was performed. 
No significant change in crude or adjusted OR was observed 
for any of the genotypes considered (Table V), further 
suggesting that none of the polymorphisms, individually 
considered, is associated with TC risk. Again, after stratifying 
data according to histological subtype, no significant change 
in crude or adjusted OR was revealed in either papillary or 
follicular TC subgroups. However, when considering only 
the papillary subtype of TC, OR values for the MUTYH 
Gln335His polymorphism almost reached significance: a 
borderline decrease in the risk of papillary TC was apparent 
for heterozygous (Gln/His) individuals (adjusted OR=0.6; 
95% CI, 0.4-1.1; P=0.080; Table V).
Finally, we evaluated whether the presence of variant 
forms in any of the selected polymorphisms was associated 
with early-age at diagnosis (i.e., predisposal to early develop-
ment of the disease) or not. The observed results (data not 
shown) do not support this hypothesis since the age at TC 
diagnosis did not differ significantly with genotype, for any of 
the polymorphisms.
Discussion
In this study, we report the role of genetic polymorphisms 
XRCC1 Arg194Trp (C➝T) and Arg399Gln (G➝A), OGG1 
Ser326Cys (C➝G), APEX1 Asp148Glu (T➝G), MUTYH 
Gln335His (G➝C) and PARP1 Val762Ala (T➝C) on the indi-
vidual susceptibility for TC. The frequencies of the different 
genotypes observed in the control population are similar to 
those reported in other Caucasian populations.
XRCC1 is a nuclear protein that, despite lacking any 
enzymatic activity, plays an important role in the efficient 
repair of SSBs and in the BER pathway: it acts as a scaffold 
protein that facilitates the recruitment of multiple DNA repair 
enzymes (such as Pol β, hOGG1, APEX1, PARP1 and LIG3) to 
lesion sites and coordinates the DNA damage repair response. 
Arg194Trp and Arg399Gln are among the most extensively 
studied XRCC1 coding region SNPs. Both polymorphisms 
have been shown to alter the functional activity of the resulting 
protein in vitro and to interfere with cancer susceptibility: 
the 194Trp allele has been associated with increased protein 
function (hence, enhanced DNA repair capacity and lower 
sensitivity to genotoxicants) and decreased risk of certain 
cancers, particularly among smokers; on the contrary, the 
399Gln allele is suggested to be associated with decreased 
DNA repair capacity and higher sensitivity to genotoxicants. 
Epidemiological evidence for an association between the 
Arg399Gln polymorphism and cancer susceptibility is weaker 
(often negative, inconsistent or conflicting) and associations 
in opposite directions depending on cancer type and smoking 
status have been suggested. Other gene-environment (e.g. 
drinking status or menopausal age) and gene-gene interactions 
(e.g. other DNA repair or chemical metabolizing enzymes) 
have also been reported for both SNPs. Numerous other 
well-powered studies and meta-analyses have not, however, 
confirmed these putative effects (reviewed in refs. 10,24). 
Overall, in face of the disparity in the results reported thus far, 
these amino acid substitutions appear to have only a modest 
(if any) impact on XRCC1 activity and cancer susceptibility 
(unless when considered together with other relevant envi-
ronmental or genetic factors). The epidemiological studies 
performed thus far in respect to the contribution of these SNPs 
to TC susceptibility have yielded conflicting results. Our results 
do not support an association between TC risk and the XRCC1 
Arg399Gln polymorphism, in agreement with the majority 
of the studies (25-28). This hypothesis should not be ruled 
out, however, since two other groups have recently reported 
a protective effect for the 399Gln allele in well-powered 
cohorts: in both studies, the 399Gln allele was associated 
with decreased risk of differentiated TC [OR=0.70; 95% CI, 
0.50-1.00; P=0.049; (29)] or papillary TC [OR=0.70; 95% CI, 
0.59-0.93; P=0.03; (30)]. On the contrary, the 194Trp allele has 
been shown to increase the risk of developing differentiated 
TC [OR=1.4; 95% CI, 0.9-2.1, for the heterozygous genotype 
(29); OR=1.85; 95% CI, 1.11-3.07 (25)]. Furthermore, Chiang 
et al (25) observed that this genetic effect came primarily from 
the subjects with LN metastasis (OR=4.54; 95% CI, 2.11-9.79; 
P=0.0001), and was also higher when the XRCC1 and PARP1 
genotypes were considered together. The results in our study 
do not reveal a significant association between the XRCC1 
Arg194Trp variant genotype and TC risk in a Caucasian 
Portuguese population. It is possible that the differences in 
194Trp allelic frequency between Caucasian and Asian popula-
tions obscured a possible association in our study. However, one 
must also recall that the 194Trp allele is often associated with 
enhanced DNA repair capacity, lower sensitivity to genotoxi-
cants and decreased risk of other cancers (see above). In line 
with this, Sigurdson et al (28) observed, in a large cohort, that 
the minor allele of the XRCC1 Arg194Trp polymorphism was 
associated with decreased thyroid nodule risk (OR=0.5; 95% 
CI, 0.3-0.9; P=0.03), describing a similar pattern of association 
for a small number of papillary TC (n=25) (28). Also, in a small 
case-control study in a Korean population (27), the 194Trp 
heterozygous genotype was significantly associated with a 
decreased risk of papillary TC (OR=0.55; 95% CI, 0.31-0.98). 
The results presented by Ho et al (29) and Chiang et al (25) 
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should therefore be interpreted with caution. It is possible that 
the XRCC1 Arg194Trp polymorphism may have opposing 
effects depending on the disease development stage, on the 
presence of different environmental risk factors or on different 
genetic backgrounds among populations. Larger studies and/
or a meta-analysis are needed in order to further clarify the 
role of the XRCC1 polymorphisms in TC susceptibility.
Concerning our data, the results do not reveal a signifi-
cant involvement of OGG1 Ser326Cys polymorphism on 
the individual susceptibility towards TC, since the genotype 
frequencies are similar in control and cancer patient popula-
tions (Table III), and no increase in TC risk was associated 
with this polymorphism (Table V). These results are in agree-
ment with those recently reported by Garcia-Quispes et al (26) 
in the only other case-control study where the influence of the 
OGG1 Ser326Cys genotype on TC risk was also evaluated. 
The OGG1 Ser326Cys polymorphism has been demonstrated 
to impair protein function (10) and, as such, has been widely 
evaluated in different case-control studies: the available 
evidence supporting an association with cancer susceptibility is 
scarce, however, with significant results being limited, mainly, 
to lung cancer (11,31). Of notice, three recently performed 
meta-analysis (31-33) did not reveal any significant associa-
tion between the OGG1 Ser326Cys polymorphism and breast 
cancer risk: these studies, taken together, suggest a minor role 
for the OGG1 Ser326Cys polymorphism in endocrine cancer 
susceptibility (as is the case of TC).
The MUTYH protein is a BER glycosylase that is 
involved in the repair of oxidative DNA lesions such as 
8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxo-dG), a stable 
oxidation product of guanine: if left unrepaired, 8-oxo-dG 
can mispair with adenine during DNA replication, leading 
to a G:C➝T:A transversion. The MUTYH protein prevents 
these transversions by excising any adenine residue misin-
corporated in the newly synthesized DNA strand opposite to 
8-oxo-dG, thus allowing a second opportunity for OGG1 to 
repair the lesion (34). MUTYH dysfunction may, therefore, 
be especially problematic for tumorigenesis in humans since 
there are no other mechanisms for repairing 8-oxo-dG/adenine 
mismatches. Accordingly, as excellently reviewed elsewhere 
(35), two germline missense mutations in the MUTYH gene 
that result in a catalytically compromised protein, Tyr165Cys 
and Gly382Asp, have been unequivocally demonstrated to 
be associated with a colorectal adenoma and carcinoma 
predisposition syndrome that is now referred to as MUTYH-
associated polyposis (MAP): MAP phenotypically resembles 
the classic or the attenuated forms of familial adenomatous 
polyposis (FAP) but is transmitted as an autosomal recessive 
trait associated with inherited biallelic defects in the MUTYH 
gene. MAP tumours display an unusually high proportion of 
somatic G:C➝T:A transversion mutations in the APC and K-ras 
genes, probably reflecting defective MUTYH protein activity 
and consequent failure to correct A:8-oxo-dG mispairs. It is 
worth mentioning that, as it has been firmly established for 
FAP patients, MAP patients may also be at increased risk 
of developing extra-colonic tumours such as TC: TC has 
sporadically been observed in MAP patients (36,37) but, for 
the time being, evidence is insufficient to establish an asso-
ciation between MAP and TC. Besides the Tyr165Cys and 
Gly382Asp variants, many other MUTYH germline mutations 
and SNPs have been described to date, most of them rare 
and/or of ‘uncertain pathogenicity’ (35). MUTYH Gln335His 
is a common polymorphism located on exon 12 (35), more 
frequently detected in Japanese and Chinese than in European 
populations. The enzyme encoded by this variant has been 
demonstrated to have partially impaired glycosylase activity 
in vitro (compared to the wild-type, the variant enzyme 
was 34% less active in removing adenine from substrates 
containing an A:GO mismatch) (38) and could therefore 
contribute to cancer susceptibility. The possible association 
between the MUTYH Gln335His polymorphism and cancer 
risk has been extensively studied in Asian (mainly Japanese) 
and other populations: the 335His variant allele has been 
suggested to be associated with increased risk of colorectal 
cancer (mainly when limited to specific anatomical locations) 
(39,40) and, less consistently, lung cancer (41). For the latter, 
however, existing evidence is conflicting or significant only 
when taking gene-gene interactions into account (42). To our 
knowledge, no significant correlation between the MUTYH 
Gln335His genotype and cancer risk has been described for 
any other type of cancer. Interestingly, an almost significant 
decrease in breast cancer risk (OR=0.80, 95% CI, 0.59-1.07) 
in MUTYH Gln335His heterozygotes (Gln/His) was reported 
in a Portuguese Caucasian population (23). Also, in a bladder 
cancer susceptibility study, gene-gene interactions among BER 
polymorphisms (including MUTYH Gln335His) were observed 
in ever smokers (43), suggesting that BER genetic variation 
might contribute to cancer risk through gene-gene and gene-
environmental interactions. To the best of our knowledge, no 
clinical association studies have been performed thus far to 
evaluate the role of the MUTYH Gln335His polymorphism on 
TC susceptibility. The results reported here for the MUTYH 
Gln335His polymorphism suggest that it is not associated with 
TC risk (Table V). However, when considering only the papil-
lary subtype of TC, OR values for the MUTYH Gln335His 
polymorphism almost reached significance: a borderline effect 
associated to a decreased risk of papillary TC was apparent 
for heterozygous (Gln/His) individuals (Table V). However, 
it should not be excluded that this effect could be related to 
sample size. This is the first time that the putative associa-
tion between the MUTYH Gln335His polymorphism and TC 
susceptibility has been evaluated. The results reported here 
strongly suggest that its role in papillary TC susceptibility 
be further evaluated in a larger study population, in order to 
verify its potential usefulness as a predictive biomarker of 
genetic susceptibility to TC.
APEX1, the major human AP endonuclease, plays a central 
role in the BER pathway due to its ability to process abasic 
sites and other 3' DNA termini that may result, for example, 
from exposure to IR or direct attack by free radicals (11). The 
APEX1 Asp148Glu polymorphism is the most common and 
most studied non-synonymous APEX1 coding region variant 
(10,11). Despite the enzyme encoded by the variant form of 
this polymorphism has been demonstrated in vitro to possess 
no significant impact on endonuclease and DNA binding 
activities, its potential role on cancer susceptibility has been 
frequently studied: as expected, the largest and strongest 
body of evidence (including four recent GWAS on breast 
cancer susceptibility and a meta-analysis on both lung and 
aerodigestive tract cancers) suggests no association between 
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the 148Glu allele and cancer risk (reviewed in ref. 10). On the 
contrary, Hu et al have demonstrated that the variant form of 
the enzyme is associated with cell cycle G2 delay in response 
to IR, therefore contributing to IR hypersensitivity (17). Also, 
the APEX1 Asp148Glu polymorphism was not shown to be 
associated with the non-medullary form of TC (25) in the only 
association study concerning TC that came to our knowledge, 
nor was it associated with thyroid nodules in a well-powered 
study involving IR-exposed populations (28). In agreement 
with this overwhelming evidence, our results do not support 
an association between APEX1 Asp148Glu polymorphism and 
TC risk, since neither the differences in genotypic frequencies 
observed between case and control groups nor ORs are statisti-
cally significant.
PARP1 is an abundant nuclear protein that can bind to 
DNA and promote the poly(ADP-ribosyl)ation of a variety of 
proteins (including itself). Among other roles, PARP1 has a 
major signalling role in DNA damage detection and repair, 
acting as a molecular nick sensor to initiate the recruitment 
of XRCC1 and other DNA repair proteins: transient binding 
of PARP1 to DNA single or double strand breaks allows for 
autoribosylation and subsequent interaction with XRCC1 and, 
possibly, a number of other DNA repair proteins (44). One 
common non-synonymous SNP, PARP1 Val762Ala, results in 
an amino acid substitution within the COOH-terminal cata-
lytic domain of the enzyme. This variant has been associated 
with reduced enzymatic activity (44) and limited capacity for 
interaction with XRCC1 (45). This may result in attenuated 
BER capacity and thus increased cancer predisposition in 
PARP1 Ala762 carriers. In fact, the variant form of the PARP1 
Val762Ala polymorphism has been associated, in several well-
powered clinical association studies, with increased cancer 
susceptibility, namely lung (44) and GI tract (45) cancers. 
Studies regarding other types of cancer, namely breast cancer 
(22,46), have failed to demonstrate an association between 
PARP1 Val762Ala genotype and cancer susceptibility. The 
results obtained in this study do not suggest any associa-
tion between PARP1 Val762Ala polymorphism and TC risk 
(Table V), in agreement with the results reported by Chiang 
et al (25) in the only other clinical association study where 
the role of PARP1 Val762Ala polymorphism on TC risk was 
assessed, suggesting that this polymorphism may not play a 
significant role in the disease. However, given the evidence 
available and the possibility for interaction with smoking 
status and/or XRCC1 genotype (25,44,45), more in depth 
studies should be pursued in order to further clarify this issue.
Concluding, our results do not reveal a significant 
involvement of XRCC1 Arg194Trp and Arg399Gln, OGG1 
Ser326Cys, APEX1 Asp148Glu, MUTYH Gln335His and 
PARP1 Val762Ala polymorphisms on the individual suscep-
tibility towards TC, mostly in aggreement with the limited 
evidence that is available specifically for TC risk. This 
was the first time that the putative association between the 
MUTYH Gln335His polymorphism and TC susceptibility 
was evaluated: when the histological stratification analysis 
was performed, we observed that the association between 
the presence of heterozygozity in the MUTYH Gln335His 
polymorphism and TC risk almost reached significance for the 
papillary subtype of TC. Since the sample size was modest, 
the possibility of a type I error should not be excluded and this 
result should, therefore, be interpreted with caution. More in 
depth studies involving larger populations should be pursued 
in order to further clarify this issue and to verify the potential 
usefulness of the MUTYH Gln335His genotype as a predictive 
biomarker of susceptibility to TC. Also, since BER genetic 
variation alone seems to have, at best, only a modest impact on 
TC susceptibility (unless when considered together with other 
relevant risk factors), future studies regarding the putative 
role of BER polymorphisms on TC risk should be powered 
to allow for the study of gene-environment (e.g. smoking and 
drinking status, IR exposure) and gene-gene (e.g. other DNA 
repair or chemical metabolizing enzymes) interactions as well 
as stratified analysis according to histological subtype and 
disease developmental stage. Haplotype analysis should also 
be considered.
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